In a report released yesterday, Charlie CY Yang from Bank of America Securities reiterated a Buy rating on Royalty Pharma (RPRX – Research ...

BofA analyst Charlie Yang raised the firm’s price target on Royalty Pharma (RPRX) to $39 from $38 and keeps a Buy rating on the shares. The ...

Atria Investments Inc trimmed its stake in Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 15.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and ...

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

This is a news collection page for Canberra. Check this page for latest news headlines covering major stories, events from Canberra and surrounding ACT. Get breaking news faster than any other ...

On Thursday, Royalty Pharma plc (RPRX) stock saw a decline, ending the day at $25.58 which represents a decrease of $-0.27 or -1.04% from the prior close of $25.85. The stock opened at $25.9 and ...

RPRX) today announced the inaugural Royalty Pharma Prize for Impact in Healthcare, which honors individuals or organizations who positively impact healthcare, was awarded to Micheal Milken. The prize ...

The market shrugged off Royalty Pharma plc's ( NASDAQ:RPRX ) solid earnings report. We think that investors might ...

This week, several dividend stocks are trading close to their 52-week lows. Here is a list of ten such stocks that are also ...

Summit Global Investments acquired a new stake in Royalty Pharma plc (NASDAQ:RPRX – Free Report) during the third quarter, ...

Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...

On Wednesday, Royalty Pharma plc (RPRX) stock saw a decline, ending the day at $26.64 which represents a decrease of $-0.90 or -3.27% from the prior close of $27.54. The stock opened at $28.13 and ...